# Grace Therapeutics, Inc.: Form 20-F for the period ended Mar 31, 2018

- Company: [Grace Therapeutics, Inc.](/companies/grce.md) (CIK 1444192)
- Form: 20-F
- Filed: 2018-06-29
- Accepted by EDGAR: Jun 29, 2018, 11:35 ET
- Period: 2018-03-31
- Accession: 0001171843-18-004911
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1444192/000117184318004911/f20f_062618p.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1444192/000117184318004911/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Operating income | 12 months, 2017-04-01 to 2018-03-31 | −CAD 19.7m | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months, 2017-04-01 to 2018-03-31 | −CAD 21.5m | ifrs-full:ProfitLoss |
| Operating cash flow | 12 months, 2017-04-01 to 2018-03-31 | −CAD 12.5m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2017-04-01 to 2018-03-31 | CAD 455.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2018-03-31 | CAD 8.2m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2018-03-31 | CAD 9.5m | ifrs-full:CurrentAssets |
| Total assets | at 2018-03-31 | CAD 23.0m | ifrs-full:Assets |
| Current liabilities | at 2018-03-31 | CAD 6.7m | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2018-03-31 | CAD 14.7m | ifrs-full:Liabilities |
| Shares outstanding | at 2018-03-31 | 25,638,215 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1444192/000117184318004911/f20f_062618p.htm

Filed Jun 29, 2018.
Source: SEC EDGAR, the filing index for accession 0001171843-18-004911. Last ingested by Listed: Nov 14, 2026, 23:10 ET. No prices; not investment advice.
